Last reviewed · How we verify
Fengshigutong Capsule
Fengshigutong Capsule is a Small molecule drug developed by Sun Yat-sen University. It is currently FDA-approved.
Fengshigutong Capsule is a small molecule that acts as a neurokinin 1 receptor antagonist. It is being studied in a clinical trial for the treatment of Ankylosing Spondylitis.
At a glance
| Generic name | Fengshigutong Capsule |
|---|---|
| Sponsor | Sun Yat-sen University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fengshigutong Capsule CI brief — competitive landscape report
- Fengshigutong Capsule updates RSS · CI watch RSS
- Sun Yat-sen University portfolio CI
Frequently asked questions about Fengshigutong Capsule
What is Fengshigutong Capsule?
Fengshigutong Capsule is a Small molecule drug developed by Sun Yat-sen University.
Who makes Fengshigutong Capsule?
Fengshigutong Capsule is developed and marketed by Sun Yat-sen University (see full Sun Yat-sen University pipeline at /company/sun-yat-sen-university).
What development phase is Fengshigutong Capsule in?
Fengshigutong Capsule is FDA-approved (marketed).
Related
- Manufacturer: Sun Yat-sen University — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing